BNP Paribas Asset Management
MPLT

BNP Paribas Asset Management’s MapLight Therapeutics MPLT Stock Holding History

BNP Paribas Asset Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.44M Buy
267,746
+119,816
+81% +$2.14M 0.01% 842
2025
Q4 		$2.6M Buy
+147,930
New +$2.48M ﹤0.01% 1012

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

BNP Paribas Asset Management's MPLT Position: Q1 2026 in Review

BNP Paribas Asset Management increased its MapLight Therapeutics (MPLT) stake by 81% in Q1 2026, buying an estimated $2.14M and bringing the position to 267,746 shares worth $5.44M. The position accounts for 0.01% of the portfolio, ranked #842.

BNP Paribas Asset Management first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • BNP Paribas Asset Management held 267,746 shares of MapLight Therapeutics worth $5.44M as of Q1 2026.
  • BNP Paribas Asset Management bought 119,816 MapLight Therapeutics shares in Q1 2026, an estimated $2.14M.
  • MapLight Therapeutics made up 0.01% of BNP Paribas Asset Management's portfolio in Q1 2026, its #842 holding.
  • BNP Paribas Asset Management first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on BNP Paribas Asset Management's 13F filing for Q1 2026, filed 14 May 2026.